摘要
目的 观察胸腺肽α1(Tα1)对原发性肝癌术后复发的影响。方法 2 0 0 0年 1月至 2 0 0 2年 12月 ,5 7例肝癌随机分为两组 ,对照组为手术切除组 (n =38) ,治疗组为手术切除加术后Tα1治疗(n =19)。结果 治疗组和对照组肿瘤复发率分别为 84 2 %比 86 8% (P =0 5 4 2 ) ,复发时间分别为7 0个月比 5 0个月 (P =0 0 6 0 5 ) ,中位生存时间分别为 10 0个月比 7 0个月 (P =0 0 0 39)。结论 Tα1有助于肝癌术后延缓复发并延长生存期。
Objective To observe the anti-recurrence effects of thymosin α 1 in patients with primary liver cancer (PLC) after hepatectomy. Methods A total of 57 patients with PLC treated in our hospital from January 2000 to December 2002 were randomized into 2 groups. The patients in group A (n=38) received hepatectomy only and those in group B (n=19) underwent hepatectomy plus thymosin α 1 therapy. Results The recurrent rate, recurrent time and the median survival in group A and group B were 86.8% vs 84.2% (P=0.542), 5.0 vs 7.0 months (P=0.0605) and 7.0 vs 10.0 months (P=0.0039), respectively. Conclusions Thymosin α 1 may delay the recurrent time and prolong survival time of patients with PLC after hepatectomy.
出处
《中华肝胆外科杂志》
CAS
CSCD
2004年第9期592-593,共2页
Chinese Journal of Hepatobiliary Surgery
基金
上海市科学技术委员会 (项目编号 0 1QB14 0 0 3 )
上海市医苑新星计划 (2 0 0 2 )
关键词
胸腺肽Α1
原发性肝癌
术后
复发
Carcinoma,hepatocellular
Recurrence
Thymosin α 1
